Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population

SARAHÍ HERRERA-GONZÁLEZ1, DENISSE AIDEÉ MARTÍNEZ-TREVIÑO1, MARCELINO AGUIRRE-GARZA1, MAGDALENA GÓMEZ-SILVA2,3, HUGO ALBERTO BARRERA-SALDAÑA4 and RAFAEL BALTAZAR REYES LEÓN-CACHÓN1

1Center of Molecular Diagnostics and Personalized Medicine, Department of Basic Sciences, Division of Health Sciences, University of Monterrey, San Pedro Garza García, Nuevo León 66238; 2Forensic Medicine Service, School of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460; 3Analytical Department of the Research Institute for Clinical and Experimental Pharmacology, Ipharma S.A., Monterrey, Nuevo León 64460; 4Laboratory of Genomics and Bioinformatics, Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, Mexico

Received July 26, 2017; Accepted October 12, 2017

DOI: 10.3892/br.2017.1009

Abstract. Discrepancies in the response to drugs are partially due to polymorphisms in genes involved in drug metabolism and transport. The frequency, pattern and impact of these polymorphisms vary among populations. In the present study, the pharmacokinetics and pharmacogenetics of atorvastatin (ATV) in a Mexican population were investigated. The study cohort exhibited differing ATV metabolizing phenotypes, and in subsequent allelic discrimination assays, single nucleotide polymorphisms in the angiotensinogen, angiotensin II type 1 receptor (AGTR1) and bradykinin B2 receptor (BDKRB2) genes were genotyped and their effects on the pharmacokinetic parameters of ATV were assessed. Additionally, association studies were performed to test for a correlation between metabolizing phenotypes and genetic variants. It was observed that carriers of the genotypes A/C and C/T in AGTR1 and BDKRB2 had higher area under the curve values from time 0 to the time of the last measurement and from time 0 extrapolated to infinity, and lower values of clearance of the fraction dose absorbed compared with homozygous carriers (P<0.05). Only the C/C genotype of BDKRB2 was associated with the fast metabolizer phenotype. These data suggest that AGTR1 and BDKRB2 are involved in ATV pharmacokinetics; a novel finding that requires confirmation in further studies.

Introduction

The prevalence of chronic degenerative diseases has increased in the adult Mexican population (1,2). In Mexico, cardiovascular disease (CVD) was a leading cause of death in 2015 (3), while hypercholesterolemia, a major risk factor for CVD, was the most prevalent type of dyslipidemia in the Mexican population between 2003 and 2005 (4). Statins are cholesterol-lowering drugs, and in 2012, atorvastatin (ATV) was the most frequently prescribed statin in Mexico (5). Within liver cells, ATV disrupts cholesterol biosynthesis by blocking 3-hydroxy-3-methylglutaryl-coenzyme A reductase, which reduces the amount of cholesterol released into the blood. As a consequence, low-density lipoprotein cholesterol uptake by liver cells increases and blood cholesterol levels diminish (6). However, in clinical trials of ATV, pharmacokinetic parameters including maximum plasma concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration-time curve (AUC) from time 0 to the time of last measurement (AUC0-t), AUC from time 0 extrapolated to infinity (AUC0-∞), apparent clearance of the fraction dose absorbed (Cl/F), elimination rate constant in the terminal drug phase (Ke) and the half-life in the terminal drug phase (T1/2) are variable (7). This reflects the underlying variability in the absorption, distribution, metabolism and excretion (ADME) processes of ATV, which may affect the pharmacological response (8). Although in general, genetic factors influence ~30% of variation in drug disposition and response (9,10), recent results have indicated that genetic variability may contribute to >90% of the variance in ATV plasma concentrations (11). These differences in the ADME characteristics of ATV have been attributed to polymorphisms in genes associated with drug pharmacokinetics, particularly those encoding enzymes and transporters (7,10,11).
The anti-inflammatory effect of statins has been investigated (12). The angiotensin II type 1 receptor (AGTR1) blocks the angiotensin II pathway and has been associated with the development of atherosclerosis (12). In addition, polymorphisms in AGTR1 have been associated with muscle toxicity in patients treated with statins (13). In addition to AGTR1, angiotensinogen (AGT) is part of the renin-angiotensin-aldosterone system (14). An improved response to diuretics has been observed in the presence of the AGTR1 A1166C and AGT G-6A polymorphisms in African-American women and a Chinese population (15,16).

The kallikrein-kinin system is also involved in multiple cardiovascular events; it modulates the renin-angiotensin-aldosterone system, promotes vasodilation, modulates neovascularization and stimulates the inflammatory response (17). Genetic variants in the bradykinin B2 receptor (BDKRB2) and endothelial nitric oxide synthase (eNOS) genes have been associated with CVD risk (18,19). Notably, the BDKRB2 C(-58)T polymorphism has been associated with hypertension in an Asian population; carriers of the C/C genotype had an increased risk, whereas carriers of the T/T genotype had a decreased risk. However, in Asian heterozygous carriers, Americans and Europeans, no association has been identified (20), though an improved response to enalapril for the treatment of hypertension has been observed in individuals with the C/C genotype (21).

Although polymorphisms in the AGTR1, AGT and BDKRB2 genes have been described, there is a lack of studies on their frequency and effect on ATV pharmacokinetics. Therefore, the present study aimed to: i) Identify novel polymorphic variants influencing the pharmacokinetic parameters of ATV; and ii) associate genotypes with metabolizing phenotypes.

Materials and methods

Design. A randomized clinical study was conducted in 60 healthy volunteers of Mexican origin to assess the bioequivalence of a single oral dose (80 mg) of ATV (coated tablets; Pfizer, Inc., New York, NY, USA) (7). The study was performed according to the guidelines of the Declaration of Helsinki (22), of Tokyo for Good Clinical Practice Standards (23), and to Mexican regulations for studies of bioavailability and bioequivalence (24). The clinical protocol was approved by the Research and Ethics Committee of the Clinical and Experimental Pharmacology Center, Ipharma S.A. (Monterrey, Mexico), and the pharmacogenetic procedure was approved by the Ethics, Research and Biosecurity Committees of the University of Monterrey (Monterrey, Mexico). The study was registered with the Federal Commission for Protection Against Health Risks under code Atorvastatina/A95-10Bis and in the Register of Clinical Trials of Australia and New Zealand (registration no. ACTRN1261400851662). Written informed consent was obtained from all subjects.

Study population. As described in our preliminary pilot study (7), a total of 60 healthy male volunteers of Mexican origin were included in the study from January 2011 to February 2011, with a mean age of 24.01±4.35 years. The inclusion criteria were as follows: Non-smoker; 18-45 years old; weight, ≥50 kg; body mass index, 20-26 kg/m²; availability to complete the study and normal health status (free from disease). Health status was assessed based on physical examination, medical history and clinical and biochemical tests. Insufficiency in any requirement (abnormal laboratory results, drug abuse, ingestion of alcohol 1 week prior to the study, prescription or over-the-counter medication prior to enrollment and reluctance to complete the study) was reason for exclusion from the study. Women were excluded as ATV is classified as a pregnancy category X drug (25).

Sampling. ATV administration and blood sampling were performed as described in the pilot study (7). Briefly, peripheral blood (4 mL) was collected in K<sub>2</sub>EDTA-coated BD Vacutainers® (BD Diagnostics, Franklin Lakes, NJ, USA) at different time points: Prior to drug administration (time 0) and at 17 time points (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36 and 48 h) after drug administration. The plasma was used for pharmacokinetic analysis and DNA was isolated from blood cells using an alkaline lysis method (26). Genomic DNA was quantified by UV absorbance using a Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). An absorbance 260/280 ratio between 1.8 and 2 was considered of adequate quality for subsequent use. The DNA concentration was adjusted to 10 ng/µl and stored at -20°C until analysis.

Pharmacokinetic analysis. ATV plasma concentrations were measured by high-performance liquid chromatography tandem mass spectrometry with an Agilent 1100 system (Agilent Technologies, Inc., Santa Clara, CA, USA) using a method validated by Ipharma S.A. (7,27,28). The C<sub>max</sub> and Tmax parameters were obtained from the concentration-time data of the plasma. Pharmacokinetic parameters including AUC<sub>0-a</sub>, AUC<sub>0-∞</sub>, Cl/F, Ke, and T<sub>1/2</sub>, were calculated with a non-compartmental method (29) using WinNonlin<sup>®</sup> software v5.3 (Pharsight Corp., Mountain View, CA, USA) as described in the pilot study (7).

Metabolic phenotype classification. The metabolizer phenotypes were determined according to the results of a multivariate analysis of the combined pharmacokinetic parameters C<sub>max</sub> and AUC<sub>0-a</sub> (7). First, C<sub>max</sub> and AUC<sub>0-a</sub> were standardized to minimize the effect of scale differences, and a distance matrix was made from the combined standardized C<sub>max</sub> and AUC<sub>0-a</sub> values. Subsequently, hierarchical cluster analysis (HCA) using the Ward linkage method (30) was performed on individual C<sub>max</sub> and AUC<sub>0-a</sub> values. Finally, the interindividual Manhattan distances were computed. Minitab 16 software (Minitab Inc., State College, PA, USA) was used for standardization and HCA.

Pharmacogenetic tests. DNA samples were genotyped for the polymorphisms AGT-rs699, AGTR1-rs5186 and BDKRB2-rs1799722 using real-time polymerase chain reaction and Taqman® probes (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. Three quality controls thresholds were applied: A genotype call rate equal to 1.0, a Hardy-Weinberg equilibrium (HWE) test with P>0.05, and a minor allele frequency of >0.01.
Statistical analysis. The HWE was determined by comparing the genotype frequencies with the expected values using the maximum likelihood method (31). All statistical analysis was performed with SPSS v20 software (IBM Corp., Armonk, NY, USA). To assess the effects of polymorphisms on the ATV pharmacokinetic parameters, comparisons between two and three groups were made. The Student's t-test and one-way analysis of variance were used for parametric distributions, while Mann-Whitney U and Kruskal-Wallis H tests were used for nonparametric distributions. To confirm the contribution of genetic factors to the variability of pharmacokinetic parameters, linear regression analysis was performed. Possible associations of genotypes or combinations of genotypes with phenotypes were evaluated using \( \chi^2 \) and Fisher's exact tests. Linear regression and associations were assessed under three different models (dominant, over-dominant and recessive) (32). The odds ratio (OR) was estimated with a 95% confidence interval (95% CI). All P-values were two-tailed. Corrected P-values (PC) were obtained using the Bonferroni correction for exclusion of spurious associations. P<0.05 was considered to indicate statistical significance.

Results

Metabolic phenotype classification. As reported in our previous study (7), the classification of metabolizer phenotypes, based on the combination of the \( C_{\text{max}} \) and \( \text{AUC}_{0-\infty} \) parameters, identified three ATV metabolizer phenotypes: Slow metabolizers (30.00%), normal metabolizers (41.66%) and fast metabolizers (28.33%). The \( C_{\text{max}} \) and \( \text{AUC}_{0-\infty} \) parameters used for the classification were significantly different between the three phenotypes (7); the parameters were significantly higher for the slow phenotype compared with the normal and fast phenotypes, and significantly higher for the normal phenotype compared with the fast phenotype (P<0.05; Fig. 1). None of the subjects reported any side effects (7).

Pharmacogenetic tests. Allele frequencies of the genetic polymorphisms were consistent with HWE (P>0.05). All genetic polymorphisms satisfied the quality control tests.

Association between genotypes and ATV pharmacokinetics. There was no significant effect of the AGT-rs699 polymorphism on ATV pharmacokinetic parameters (Table I). Conversely, \( \text{AUC}_{0-t} \) and \( \text{AUC}_{0-\infty} \) values were significantly higher in individuals with the heterozygous genotype (A/C) of the AGTR1-rs5186 polymorphism when compared with the C/C genotype (P<0.05). In addition, the \( \text{AUC}_{0-\infty} \) of the A/C genotype was increased compared with that observed for the combination of the homozygous wild-type and homozygous variant alleles (A/A+C/C; P<0.05). In heterozygous carriers, CI/F and AUC/F values were significantly lower than those observed for homozygous variant allele carriers (C/C) and for the combination of homozygous alleles (A/A+C/C; P<0.05; Table I and Fig. 2A and B).

For BDKRB2-rs1799722, carriers of the heterozygous genotype (C/T) were identified to have significantly higher values of \( \text{AUC}_{0-t} \) (P=0.021) and \( \text{AUC}_{0-\infty} \) (P=0.023) and lower values of CI/F (P=0.007) compared with those obtained for the combination of homozygous alleles (C/C+T/T; Table I and Fig. 2C and D).

The linear regression analysis under the over-dominant genetic model indicated that the AGTR1-rs5186 polymorphism significantly affected the values of T\(_{1/2}\) (adjusted \( R^2 = 0.053, P = 0.043 \)); however, on comparison of the means by genotype, no significant differences were observed. Similarly, the BDKRB2-rs1799722 polymorphism significantly affected the CI/F values (adjusted \( R^2 = 0.093, P = 0.01 \); data not shown).

Association between genotypes and metabolizer phenotypes. Of the two polymorphisms with an effect on ATV pharmacokinetics, BDKRB2-rs1799722 was associated with fast metabolism when considering genetic models; association analysis using the dominant model identified that the C/C

Table I. Effect of polymorphisms on the pharmacokinetic parameters of atorvastatin.

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>N</th>
<th>( C_{\text{max}} ) (ng/ml)</th>
<th>( \text{AUC}_{0-t} ) (ng/ml/h)</th>
<th>( \text{AUC}_{0-\infty} ) (ng/ml/h)</th>
<th>CI/F (l/h)</th>
<th>Ke</th>
<th>T(_{1/2}) (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGT-rs699</td>
<td>A/A</td>
<td>4</td>
<td>45.72±11.03</td>
<td>109.72±38.89</td>
<td>121.44±33.81</td>
<td>729.06±266.90</td>
<td>0.05±0.02</td>
</tr>
<tr>
<td>A/G</td>
<td>29</td>
<td>43.21±21.06</td>
<td>141.98±51.00</td>
<td>159.05±56.37</td>
<td>588.08±279.10</td>
<td>0.07±0.04</td>
<td>12.43±7.99</td>
</tr>
<tr>
<td>G/G</td>
<td>27</td>
<td>51.20±26.65</td>
<td>189.40±11.65</td>
<td>200.34±110.61</td>
<td>516.63±246.52</td>
<td>0.08±0.02</td>
<td>9.22±3.25</td>
</tr>
<tr>
<td>A/A+G/G</td>
<td>33</td>
<td>43.51±20.00</td>
<td>138.07±50.32</td>
<td>154.49±55.82</td>
<td>605.17±277.53</td>
<td>0.07±0.04</td>
<td>12.74±8.09</td>
</tr>
<tr>
<td>AGTR1-rs5186</td>
<td>A/A</td>
<td>34</td>
<td>44.14±22.86</td>
<td>155.21±83.44</td>
<td>166.63±81.73</td>
<td>585.92±269.36</td>
<td>0.08±0.03</td>
</tr>
<tr>
<td>A/C</td>
<td>21</td>
<td>54.80±23.47</td>
<td>186.44±92.45</td>
<td>204.55±94.76</td>
<td>473.67±220.44</td>
<td>0.06±0.03</td>
<td>13.49±8.12</td>
</tr>
<tr>
<td>C/C</td>
<td>5</td>
<td>33.36±18.79</td>
<td>95.57±43.10</td>
<td>109.28±40.84</td>
<td>810.19±275.81</td>
<td>0.07±0.02</td>
<td>10.72±3.30</td>
</tr>
<tr>
<td>A/A+C/C</td>
<td>39</td>
<td>42.76±22.46</td>
<td>147.56±81.54</td>
<td>159.28±79.71</td>
<td>614.68±277.11</td>
<td>0.08±0.03</td>
<td>9.90±5.27</td>
</tr>
<tr>
<td>BDKRB2-rs1799722</td>
<td>C/C</td>
<td>24</td>
<td>44.00±27.21</td>
<td>151.53±103.77</td>
<td>163.00±102.00</td>
<td>649.67±316.78</td>
<td>0.09±0.02</td>
</tr>
<tr>
<td>C/T</td>
<td>27</td>
<td>51.80±20.93</td>
<td>180.66±78.48</td>
<td>194.17±77.38</td>
<td>469.55±168.36</td>
<td>0.07±0.04</td>
<td>12.64±7.21</td>
</tr>
<tr>
<td>T/T</td>
<td>9</td>
<td>40.40±17.73</td>
<td>128.38±42.26</td>
<td>150.31±66.35</td>
<td>627.71±287.80</td>
<td>0.06±0.02</td>
<td>13.05±5.53</td>
</tr>
<tr>
<td>C/C+T/T</td>
<td>33</td>
<td>43.02±24.76</td>
<td>145.22±91.08</td>
<td>159.54±92.80</td>
<td>643.68±304.85</td>
<td>0.08±0.02</td>
<td>9.94±5.84</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation. *P=0.015 (A/C vs. C/C), *P=0.040 (A/A+C/C vs. A/C), *P=0.021 (C/C+T/T vs. C/T), *P=0.007 (C/C+T/T vs. C/T), **P=0.007 (C/C+T/T vs. C/T), **P=0.023 (C/C+T/T vs. C/T).
Table II. Association between genotypes and metabolizer phenotypes.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Polymorphism</th>
<th>Model</th>
<th>OR (95% CI)</th>
<th>P-value</th>
<th>Pc-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDKRB2</td>
<td>rs1799722</td>
<td>Dominant (C/C vs. C/T+T/T)</td>
<td>C/C: Fast metabolizers 0.014 0.47 (0.26-0.83)</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C/T+T/T: Normal/slow metabolizers 1.98 (1.01-3.88)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDKRB2</td>
<td>rs1799722</td>
<td>Over-dominant (C/C+T/T vs. C/T)</td>
<td>C/C+T/T: Fast metabolizers 0.036 0.68 (0.40-0.92)</td>
<td>0.07</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C/T: Normal/slow metabolizers 2.27 (0.92-5.60)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BDKRB2, bradykinin B2 receptor; OR, odds ratio; CI, confidence interval; Pc, Bonferroni-corrected P-values.

Figure 2. AGTR1 and BDKRB2 genotypes based on atorvastatin pharmacokinetics. (A) Mean values of AUC0‑∞ for the genotypes and genotype combinations of AGTR1-rs5186; (B) mean values of Cl/F for the genotypes and genotype combinations of AGTR1-rs5186; (C) mean values of AUC0‑∞, AUC from time 0 to the time of last measurement; AUC0‑∞, area under the plasma concentration-time curve from time 0 to the time of last measurement.
Discussion

The pharmacokinetic parameters of ATV, namely C_{max} and AUC, may vary by >10-fold (7,33). Following analysis of pharmacokinetic discrepancies, three major metabolizer phenotypes of ATV have been identified in Chinese and Mexican populations (7,33). This variation has been associated with polymorphisms in genes encoding drug metabolizing enzymes and transporters (34). However, differences in allele frequencies and their effect on quantitative parameters including cholesterol levels, arterial pressure and pharmacokinetic parameters, and associations of genotypes with drug metabolism and response have been documented across various populations (7,33,35,36).

In the current study, the effect on ATV pharmacokinetics of three polymorphic variants in genes related to drug metabolism and response were evaluated. AGT-rs699 had no significant effect on pharmacokinetic parameters. However, to the best of our knowledge, the study is the first to identify an effect of AGTR1-rs5186 and BDKRB2-rs1799722 on ATV pharmacokinetics.

Heterozygous carriers of rs5186 (A/C) exhibited higher AUC_{0-∞} and AUC_{0-t} values, while having lower Cl/F values, than homozygous carriers (C/C), which thus indicates a diminished clearance activity and longer permanence of ATV in heterozygous carriers. The effect of the AGTR1 polymorphism on T_{1/2} was consistent with this interpretation. This decreased clearance and longer exposure to ATV may lead to an improved response to drug therapy, or to an adverse effect. By contrast, carriers of homozygous genotypes (A/A or C/C) had increased clearance, and thus may have a poorer response to treatment. However, there was no association between the A/A or C/C genotypes with the fast metabolizer phenotype. To the best of our knowledge, this is the first report on the influence of rs5186 on ATV pharmacokinetics, though the rs5186 polymorphism has previously been associated with lipid levels (37), and ATV, as a statin, has lipid-lowering effects (38). Consistent with the present results, the C/C genotype has been related to higher levels of triglycerides in a healthy Malayan population (37). Additionally, in a case-control study conducted in a Northern Indian population, the C/C genotype was associated with essential hypertension and higher gene expression of AGTR1 (39). Regarding the anti-inflammatory effect of statins, ATV may affect activation of the angiotensin pathway through AGTR1 by attenuating the activity of angiotensin II (ANG II), as observed in rats, whereby ATV modulated ANG II-induced expression of inflammatory and fibrogenic genes in the liver (40); however there is a lack of data regarding the association of AGTR1-rs5186 with the anti-inflammatory response.

Regarding BDKRB2-rs1799722, significant differences in the AUC_{0-∞}, AUC_{0-t} and Cl/F parameters were identified between heterozygous carriers (C/T) and homozygous carriers (C/C or T/T). The current results suggest that the BDKRB2-rs1799722 polymorphism affects ATV clearance activity. This effect was demonstrated by linear regression and association analyses under over-dominant and dominant models. Notably, it was indicated that the C allele promotes fast metabolism, while accumulation of the T allele leads to a shift towards slower metabolism. However, the pharmacokinetic parameters of the T/T homozygous carriers did not differ significantly compared with heterozygous carriers. To the best of our knowledge, BDKRB2-rs1799722 has not previously been associated with statin metabolism. However, a meta-analysis identified that the C allele of rs1799722 increased the risk of hypertension in Asian and African-American populations (20). A pharmacogenetic study conducted in a Brazilian population revealed that carriers of the C allele responded to Enalapril, an antihypertensive drug that serves as an inhibitor of angiotensin-converting enzyme (21). The statins are also established for their antihypertensive effects in hypercholesterolemic patients (41). Nonetheless, there is a lack of studies into the effect of BDKRB2-rs1799722 on the metabolism or response of patients to statins.

Although a number of polymorphisms have been suggested as candidate responsible for the pharmacokinetic variability of ATV, the present study is the first to indicate the involvement of AGTR1-rs5186 and BDKRB2-rs1799722. The inclusion of these biomarkers in future studies may improve the prediction of the pharmacokinetic variability of ATV or decrease the number of variants required for prediction (7,11). While the current study demonstrated the contribution of genetic polymorphisms to ATV pharmacokinetics, there were a number of limitations. Firstly, there was a lack of data, such as cholesterol levels at one month post-treatment, for complete analysis of polymorphism effect on response. Secondly, in some cases the number of subjects per genotype was small, and thus associations may have been lost following correction. To validate the results, further studies should be performed in a larger population. In addition, the influence of other genes may explain the lack of association with the slow metabolizer phenotype.

In conclusion, a significant effect of AGTR1-rs5186 and BDKRB2-rs1799722 on ATV pharmacokinetics was detected. The present findings suggest that the A/C genotype of AGTR1-rs5186 is associated with slow ATV metabolism, while the C/C or A/A+C/C genotypes are associated with fast metabolism. Additionally, the C/T genotype of BDKRB2-rs1799722 may be associated with the slow metabolizer phenotype, while the homozygous genotypes may be associated with the fast metabolizer phenotype. These novel findings increase the panel of potential genetic biomarkers associated with ATV metabolism, and should be verified in future pharmacogenetic studies in larger populations with different genetic backgrounds.

Acknowledgements

The authors would like to thank the University of Monterrey, Italy, for funding the current study (grant no. UIN15009)
and Dr Irene Meester from the University of Monterrey for reviewing and improving the manuscript.

References


17. Solorzano-Flores LI: Official Mexican Standard NOM-177-SSA1-1998, establishing tests and procedures to demonstrate that a drug is interchangeable. Requirements must be subject to third party authorized to perform the tests. Secretaría de Salud, Mexico, 1999.


